About gni ltd - GNIIF
GNI Group Ltd. engages in the development, research, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines. It operates through the following geographical segments: Japan and China. The Japan segment deals with licensing, preclinical studies, clinical trials, and sales. The China segment covers the integrated bio-pharma operations consisting of validation, preclinical trials, formulation, phase I to III clinical trials, manufacturing and sales. The company was founded on November 20, 2001 and is headquartered in Tokyo, Japan.
GNIIF At a Glance
GNI Group Ltd.
Nihonbashi-Honcho YS Building, 3/F
Tokyo, Tokyo 103-0023
| Phone | N/A | Revenue | 155.86M | |
| Industry | Biotechnology | Net Income | 7.25M | |
| Sector | Health Technology | Employees | 867 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
GNIIF Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 149.419 |
| Price to Sales Ratio | 7.218 |
| Price to Book Ratio | 4.686 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 418.953 |
| Enterprise Value to Sales | 7.748 |
| Total Debt to Enterprise Value | 0.119 |
GNIIF Efficiency
| Revenue/Employee | 179,767.107 |
| Income Per Employee | 8,361.376 |
| Receivables Turnover | 3.887 |
| Total Asset Turnover | 0.346 |
GNIIF Liquidity
| Current Ratio | 2.344 |
| Quick Ratio | 2.142 |
| Cash Ratio | 1.037 |
GNIIF Profitability
| Gross Margin | 76.391 |
| Operating Margin | -2.315 |
| Pretax Margin | 0.972 |
| Net Margin | 4.651 |
| Return on Assets | 1.61 |
| Return on Equity | 3.074 |
| Return on Total Capital | 1.928 |
| Return on Invested Capital | 2.065 |
GNIIF Capital Structure
| Total Debt to Total Equity | 62.174 |
| Total Debt to Total Capital | 38.338 |
| Total Debt to Total Assets | 31.497 |
| Long-Term Debt to Equity | 47.714 |
| Long-Term Debt to Total Capital | 29.421 |